I learned about Twist in October 2021, when I shared a link from Alex Danco. He was excited about an API for biotech, enabling a new class of bio founders. In April 2022 I was impressed by Twist’s CEO speaking on a podcast about […]
“As biotech businesses become more specialized, I find that it can be useful to stratify biotech platforms into two buckets: target companies and modality companies. So far, AI advances have been more valuable for modality companies than for target companies. […]
“Chicago isn’t necessarily synonymous with its spot as a biopharma hotbed – however, due to new investments, governmental support, collaborations and prominent academic institutions, this is changing.” | learn more
Part 2 of the 4-part series I started sharing last week. Former Google CEO Eric Schmidt gave a talk at a biology conference and said that he felt “your industry is at the same stage mine was in 40 years […]
Elad Gil defends Silicon Valley tech startups, making the case that Theranos is not representative of them. “Theranos raised no real mainstream venture capital. None of the mainstream tech or biotech funders invested in Theranos.” | learn more
“Next-gen skincare, silk without spiders and pollution for lunch.” | learn more
“As with startups, biotech companies have high failure rates: 90% of clinical programs fail to receive FDA approval, while 92% of biotech companies are unprofitable at any given time.” | learn more